Polymorphisms attenuating IL-10 signalling confer genetic risk for inflammatory bowel disease. Yet, how IL-10 prevents mucosal autoinflammation is incompletely understood. We demonstrate using lineage-specific deletions of IL-10Rα that IL-10 acts primarily through macrophages to limit colitis. Colitis depends on IL-6 to support pathologic Th17 cell generation in wild-type mice. However, specific ablation of macrophage IL-10Rα provokes excessive IL-1β production that overrides Th17 IL-6 dependency, amplifying the colonic Th17 response and disease severity. IL-10 not only inhibits pro-IL-1β production transcriptionally in macrophages, but suppresses caspase-1 activation and caspase-1-dependent maturation of pro-IL-1β to IL-1β. Therefore, lineage-specific effects of IL-10 skew the cytokine dependency of Th17 cell development required for colitis pathogenesis. Coordinated interventions may be needed to fully suppress Th17-mediated immunopathology.
Polymorphisms attenuating IL-10 signalling confer genetic risk for inflammatory bowel disease. Yet, how IL-10 prevents mucosal autoinflammation is incompletely understood. We demonstrate using lineage-specific deletions of IL-10Rα that IL-10 acts primarily through macrophages to limit colitis. Colitis depends on IL-6 to support pathologic Th17 cell generation in wild-type mice. However, specific ablation of macrophage IL-10Rα provokes excessive IL-1β production that overrides Th17IL-6 dependency, amplifying the colonic Th17 response and disease severity. IL-10 not only inhibits pro-IL-1β production transcriptionally in macrophages, but suppresses caspase-1 activation and caspase-1-dependent maturation of pro-IL-1β to IL-1β. Therefore, lineage-specific effects of IL-10 skew the cytokine dependency of Th17 cell development required for colitis pathogenesis. Coordinated interventions may be needed to fully suppress Th17-mediated immunopathology.
Inflammatory bowel diseases (IBD), including Crohn’s disease and
ulcerative colitis, are characterized by chronic relapsing intestinal inflammation
and disorganized immune responses in the gastrointestinal tract[1]. Although IBD pathogenesis is incompletely
understood, mucosal T-helper type 17 (Th17) cells play a key pathologic
role[2-4]. Th17 induction is supported by
IL-1β, IL-6, IL-23 and TGF-β[5-7], cytokines
that upregulate and stabilize retinoic acid receptor-related organ receptor
(RORγT) and pro-inflammatory function[8].The cytokine IL-10 preserves gastrointestinal homeostasis[9]. Mice deficient in IL-10 or IL-10Rβ
develop spontaneous enterocolitis[10,
11]. Bi-allelic mutations in
IL-10 lead to infantile enterocolitis, polymorphisms in IL-10 are associated with
ulcerative colitis and Crohn’s disease, and an association has been further
reported between IL-10Rα SNPs and early onset UC[12-15].Dynamic interactions between IL-10 and different IL-10 responsive immune cell
lineages participate in IBD pathogenesis[16]. Mice with a deletion of IL-10 or its receptor solely in
Foxp3+ T cells can develop spontaneous colitis[17, 18]. The IL-10R-deficient Foxp3+ T cells
display decreased IL-10 secretion itself, potentially linking these phenotypes.
Further, two recent studies have implicated the IL-10 response by myeloid
populations to mucosal homeostasis and colitis susceptibility. Zigmond, et. al. used
a CX3CR1 promoter-directed Cre to selectively delete IL-10Rα. These mice
developed spontaneous colitis, and implicated IL-10 in the generation of
anti-inflammatory CX3CR1+ myeloid cells necessary for colonic
homeostasis[19]. Shouval,
et. al. demonstrated that IL-10Rβ−/−
Rag2−/− mice are susceptible to colitis mediated by
total CD4 T cell transfer. The IL-10Rβ deficiency impedes the generation and
activity of anti-inflammatory macrophages, and impairs iTreg generation and Treg
function[20].
IL-10-producing myeloid cells have also been shown to prevent the downregulation of
Foxp3 in T cell transfer colitis, indicating a central role for IL-10 in the
crosstalk between regulatory T cell and myeloid populations[21]. Implicating IL-10 in T cell effector
function as well, T cell-specific blockade of IL-10 signaling using a dominant
negative IL-10 receptor (IL-10RDN) leads to increased Th17 cells in an anti-CD3 Ab
induced model of small intestinal inflammation[22].Despite the clear role of IL-10 in intestinal homeostasis, pharmacologic
administration of IL-10 has not proven effective[23]. Further resolution of the core interactions, responsible
cell types, and pertinent mechanisms underlying IL-10’s activity will be
necessary to develop effective interventions targeting this pathway. Here we use the
transfer of naive CD4+CD45RBhi T cells into
lymphocyte-deficient strains to analyze how the lineage specific activities of IL-10
impact the pathologic T cell response.Transferred naïve T cells are activated by microbial flora, provoking
Th17-dependent colonic inflammation. Studies using IL-10RDN T cells have indicated
that the T cell IL-10 response does not significantly restrain colitis development
after CD45RBhi T cell transfer[24]. We verify this here using T cells conditionally deficient
in the specific receptor for IL-10, IL-10Rα. However, we further show using
additional targeted deletion models that IL-10 acts dominantly on macrophages
(Mϕs) to mediate its inhibitory effects, and define how this occurs through
a shift in the cytokine dependency of pathologic effector T cells. We show that
IL-10 acts on Mϕs to potently suppress IL-1β production through
several routes, including the inhibition pro-IL-1β production, caspase-1
activation, and IL-1β maturation. This not only modulates colitis, but also
transforms the pathologic Th17 response from one that is IL-6-independent and
IL-1-dependent to one with an obligate requirement for IL-6. Our findings
demonstrate a redundancy in operative Th17 induction pathways during colitis, the
critical role of the Mϕ response to IL-10 in controlling these pathways, and
imply that coordinated therapies targeting redundant cytokines may be required to
fully suppress disease.
Results
T cell IL-10 response does not impact colitis development
To evaluate lineage-specific effects of IL-10 in T cell transfer-mediated
colitis, we first produced mice with a selective deletion of the specific IL-10
receptor, IL-10Rα, restricted to T cells
(IL-10RαTdel)[25]. Colitis was then induced by transferring naive
CD4+CD25−CD45RBhi T cells
from wild-type (WT) or IL-10RαTdel mice into
Rag1−/− recipients. Disease magnitude and quality
were monitored through changes in body weight, colon histopathology, and colonic
T cell and T cell subset (Th1, Th17, Foxp3+) infiltration
(Supplementary Fig.
1). No differences were identified between recipients of WT and
IL-10RαTdel T cells, indicating that IL-10 signaling into
the transferred T cells does not modulate colitis severity in this T
cell-dependent model.
Mϕ response to IL-10 restrains T cell-mediated colitis
We previously demonstrated that macrophage but not DC or T cell IL-10
signaling prominently alleviated inflammation in a distinct T cell-independent,
toxin-induced model of acute colitis, DSS colitis[26]. Recent data have also implicated
myeloid cells as regulators of disease severity in T cell transfer
colitis[19-21]. To assess the impact of DC
and Mϕ-selective deletion of IL-10Rα
(IL-10RαDCdel, IL-10RαMdel) in T cell
transfer colitis, we generated lineage-specific knock-outs on a
Rag1−/− background and induced disease.
Histologic and clinical disease did not differ between
Rag1−/− and
IL-10RαDCdelRag1−/− recipients
(Supplementary Fig. 2a,
b). In contrast, disease was intensified in
IL-10RαMdelRag1−/− mice (Fig. 1a and Supplementary Fig. 2a, b). Weight
loss was elevated and accelerated, with a mean±s.e.m. decrement at 8 wk
of 19.1±1.1% vs 9.3±1.1% for
Rag1−/− controls (Fig. 1a).
IL-10RαMdelRag1−/− colons were
shorter than Rag1−/− controls (8.2±0.3 vs
7.1±0.2 cm, Fig. 1b).
Histopathology in
IL-10RαMdelRag1−/− colons
demonstrated increased inflammation, with more extensive cellular infiltrates,
submucosal edema, and epithelial erosion (Fig.
1c). Total histologic score was 8.3±0.6 and 3.6±0.7
(scale 0–12) for
IL-10RαMdelRag1−/− and
Rag1−/− mice respectively. Moreover, fewer
IL-10RαMdelRag1−/− mice
survived with extended disease times (Fig.
1d), and these developed an elevated incidence of rectal prolapse
(75% IL-10RαMdelRag1−/−
mice vs 0% Rag1−/− controls at 12 wk).
Figure 1
Mϕ IL-10Rα expression attenuates T cell-induced
colitis
(A) CD4+CD25−CD45RBhi C57BL/6 T
cells (5×105) were transferred into C57BL/6
Rag1−/− and
IL-10RαMdelRag1−/− mice to
induce colitis. Mean±1 s.e.m. percent of initial body weight is plotted.
*, p<0.05; **, p<0.01;
***, p<0.001 (by t-test); (B) Colons were removed at
week 8 and colon length measured from the indicated recipients or mice not
receiving T cells (control). (C) Representative photomicrographs and tallied
scores for disease parameters from H&E stained colon sections obtained 8 wk
after naive T cells transfer. (D) Kaplan-Meier survival curves of
Rag1−/− and
IL-10RαMdelRag1−/− mice
(n=10). (E) Colitis was induced in Rag1−/−
and IL-10RαMdelRag1−/− mice with
5×105
CD4+CD25−CD45RBhi T cells
from C57BL/6 mice. Anti-Ly6G or control Ab was administered i.p. 1 d
pre-transfer and then weekly to deplete neutrophils. Mean±1 s.e.m.
initial body weight is plotted (n=10/cohort). △,
Rag1−/− vs
Rag1−/−+ αLy6G; ○,
Rag1−/− vs
IL-10RαMdelRag1−/−; *,
Rag1−/−+ αLy6G vs
IL-10RαMdelRag1−/−+
αLy6G; p<0.05, p<0.01, and p<0.001 for 1, 2, and 3 symbols (by
ANOVA). No significant difference was seen in
IL-10RαMdelRag1−/− vs
IL-10RαMdelRag1−/−+
αLy6G. (F) Histology scores for 8 week colon from mouse cohorts treated
as in (e). Data are representative of three independent experiments,
n=5–10 per cohort.
In a recent study, mice deleting IL-10R using a CX3CR1-driven Cre that is
expressed by a large proportion of LPMϕs developed spontaneous colitis.
We did not observe overt spontaneous disease in our
IL-10RαMdelRag1−/− mice during
the time frame of our assays. To further assess this, cohorts of these and
IL-10Rαfl/flRag1−/− controls
(n=10 for each) were aged for 6 months. There was no difference in
weight gain, or presence of clinical signs of colitis or other illness in either
population (Supplementary Fig.
2c). Histologic analysis of 5 aged
IL-10RαMdelRag1−/− mice failed
to identify evidence for colitis. Similarly, spontaneous colitis was not
observed in 6 month aged
IL-10RαMdelRag1+/+ mice.IL-10’s protective role in colitis is well established. To
determine whether the Mϕ-specific response to IL-10 can account for
this, we also compared disease in
IL-10RαMdelRag1−/− mice with
Rag1−/− mice harboring a germline deletion in
IL-10Rα
(IL-10Rα−/−Rag1−/−;
Supplementary Fig. 2a,
b). No difference in clinical disease or histopathology was evident
in these two recipient lines, implying that IL-10-mediated immunoprotection can
largely be accounted for by its Mϕ-specific effects.The Lys-M-Cre transgene used to ablate IL-10Rα in the
IL-10RαMdelRag1−/− mice is
expressed in granulocytes as well as Mϕs[27]. Neutrophils have a modest protective
role in T cell transfer colitis[28], and loss of IL-10Rα signaling there, rather than
in Mϕs, may have impacted disease. To isolate the Mϕ-specific
effect, we depleted neutrophils with specific Ab beginning prior to T cell
transfer. Neutrophils were undetectable in the peripheral blood from
αLy6G Ab but not control Ab treated animals throughout the experimental
interval. In Rag1−/− recipients, weight loss was
mildly increased on some disease days in neutrophil-depleted mice, though no
significant difference in histopathology was identified (Fig. 1e, f). No significant change in disease severity
was apparent with neutrophil depletion in
IL-10RαMdelRag1−/− mice.
Further, the prominent disease exacerbation in
IL-10RαMdelRag1−/− compared
with Rag1−/− recipients persisted after neutrophil
depletion, indicating that the intensified immunopathology in
IL-10RαMdelRag1−/− mice is
primarily attributable to the Mϕ rather than granulocyte IL-10
response.
Increased numbers and activation of
IL-10RαMdelRag1−/−
LPMϕs
To identify causes of the enhanced
IL-10RαMdelRag1−/− disease, we
first analyzed lamina propria macrophages (LPMϕs). LPMϕs, typed
as
CD11bhiCD11c−/lo/modF4/80+Ly6G−/loSiglecF−,
were significantly increased in
IL-10RαMdelRag1−/− mice with
colitis compared with Rag1−/− controls (Fig. 2a). This population was uniformly
CD64+ and predominantly CX3CR1+,
further delineating them as LPMϕs[29, 30] (Supplementary Fig. 3a).
The cells were further characterized by a uniformly elevated surface expression
of activation markers, including CD40, CD80, and CD86 (Fig. 2b). Segregation of
CD11b+CD64+CD103−
and CD45+ cells based on Ly6C and class II MHC expression can
distinguish pro-inflammatory (Ly6Chi) and anti-inflammatory
(Ly6Clo) macrophage populations[20, 30]. Most LPMϕs analyzed using this alternative gating
strategy were phenotypically pro-inflammatory, and the proportions of
Ly6Chi and Ly6Clo macrophages did not differ between
IL-10RαMdelRag1−/− mice and
Rag1−/− controls (Supplementary Fig. 3b).
Figure 2
Analysis of lamina propria macrophages
(A) Cells were isolated from large intestine lamina propria of
Rag1−/− and
IL-10RαMdelRag1−/− mice at wk
8 after colitis induction. Absolute numbers of LPMϕ
(CD11bhiCD11c−/lo/modF4/80+Ly6G−/loSiglec-F−)
were quantified. (B) Staining of LPMϕ gated as above, for CD40, CD80 and
CD86. Gray line, isotype control; dashed black line, LPMϕs from
Rag1−/− mice; Solid black line, LPMϕs
from IL-10RαMdelRag1−/− mice. (C).
Rag1−/− and
IL-10RαMdelRag1−/− mice
received 5×105
CD4+CD25−CD45RBhi C57BL/6 T
cells. After 8 wk, BrdU was administered i.p. and the mice sacrificed 24 h
later. Colon LP cells were isolated and BrdU positive Mϕs, DCs,
neutrophils and CD4+ T cells measured by intracellular flow
cytometry. Data are representative of three independent experiments,
n=8–10 per cohort. **, p<0.01 (by
t-test).
The increased
IL-10RαMdelRag1−/− versus
Rag1−/− LPMϕ numbers were further
associated with an increased proliferation rate, as determined by incorporation
of the nucleotide analog BrdU. Unlike for LPMϕs, no differences in BrdU
incorporation were evident in colonic CD4 T cells, DCs, and neutrophils, or in
Mϕs from other locations (Fig. 2c).
Therefore, numbers, proliferation, and activation state of LPMϕs are
increased in IL-10RαMdelRag1−/−
mice.
Unimpaired IL-10RαMdelRag1−/− T
regulatory response
A subset of T cells transferred into Rag1−/−
mice upregulate Foxp3, and IL-10 signaling into Mϕs could contribute to
the generation and maintenance of these regulatory T cells[21, 22]. Indeed, recent findings with
IL-10Rβ−/−Rag2−/−
mice have identified defective iTreg formation and Treg function. Treg
co-transferred with naïve T cells even at a 1:1 ratio were incapable of
preventing disease[20]. To
assess Treg activity here, we quantified Foxp3+ iTreg forming
in the LP, mesenteric lymph nodes (MLNs), and spleen of
IL-10RαMdelRag1−/− and control
Rag1−/− colitic mice. No differences were
observed (Fig. 3a). We next analyzed
whether sorted Treg transferred into
IL-10RαMdelRag1−/− and
Rag1−/− mice with the induction of colitis could
prevent disease. The transferred cells were able to fully suppress disease
development in both
IL-10RαMdelRag1−/− and
Rag1−/− recipients, indicating that a
macrophage-specific defect in IL-10 response does not overtly impact Treg
suppressive activity in this setting (Fig.
3b). Treg transfers led to a >2-fold increase in Treg in the
spleens, MLNs, and colons of recipient mice and Treg percentages did not differ
between IL-10RαMdelRag1−/− and
Rag1−/− recipients in any of the locations (Fig. 3c). These results indicate that Treg
are able to suppress disease in the absence of a macrophage-specific response to
IL-10, and that Treg-specific mechanisms independent of IL-10 actions on
macrophages are employed in this system.
Figure 3
T cell Foxp3 expression and IL-10 production
(A) Colitis was induced in Rag1−/− and
IL-10RαMdelRag1−/− mice by the
transfer of 5×105
CD4+CD25−CD45RBhi C57BL/6 T
cells. The frequency of Foxp3+ Treg cells among
CD4+ T cells in the spleen, MLN and colon 8 wk after
initial T cell transfer is plotted. (B) Mice received sorted
CD4+CD45RbloFoxp3-YFP+ Treg
with naive T cells at a 1:1 ratio or naive
(CD4+CD45RbhiFoxp3-YFP−)T
cells alone, and were monitored for weight loss. **, p<0.01
for naïve T→Rag1−/− vs naïve
T→IL-10RαMdelRag1−/−
(by ANOVA). Differences were not significant between naïve
T+Treg→Rag1−/− vs naïve
T+Treg
→IL-10RαMdelRag1−/−
cohorts. (C) Splenic, MLN, and colonic Foxp3+ T cells were
identified by flow cytometry in mice receiving or not receiving Treg as in
(B).Upper-left and right plots depict results for colonic Treg. Lower-left plot
depicts results for MLN and splenic Treg only in mice receiving supplemental
Treg. ***, p<0.001 (by ANOVA). (D) Similar transfers
were performed using
CD4+CD25−CD45RBhi T cells
from IL-10-GFP donors. Representative dot plots and summary analysis of the
frequency of IL-10-GFP+ cells among CD4+ T
cells in the spleen, MLN, and colon at 8 wk is shown. (E)
Rag1−/− and
IL-10RαMdelRag1−/− mice
received 5×105
CD4+CD25−CD45RBhi T cells
from C57BL/6 or IL-10−/− mice. Mean±1 s.e.m.
percent initial body weight is plotted. *,
WT→Rag1−/− vs
WT→IL-10RαMdelRag1−/−;
●,
IL-10−/−→Rag1−/−
vs
IL-10−/−→IL-10RαMdelRag1−/−;
p<0.05, p<0.01, and p<0.001 for 1, 2, and 3 symbols (by ANOVA).
Representative of 3 independent experiments, n=5 per cohort. (F).
Histological scores for colons from the indicated mice at 8 wk.
Alternative regulatory T cell populations are demarcated by IL-10
production, and IL-10 itself may impact these directly or indirectly. To
evaluate this, we induced colitis by transferring naïve T cells from
IL-10-GFP knock-in reporter mice. Here too, no differences in population sizes
were seen (Fig. 3d). To determine if T cell
IL-10 production was itself functionally dispensable for the differential
colitis in IL-10RαMdelRag1−/−
mice, we performed transfers using IL-10−/− or WT T
cells. Disease severity, measured clinically and histologically, was exclusively
associated with recipient type. IL-10 production by transferred T cells did not
influence disease magnitude clinically or histologically (Fig. 3e, f). Therefore, the Mϕ IL-10 response
does not identifiably impact regulatory T cell presence. Further, while
Mϕ response to IL-10 is critical in attenuating disease, T cells are not
a significant source of this IL-10 here.
Pro-inflammatory cytokine production by IL-10RαMdel
LPMϕs
To further evaluate the heightened disease severity in
IL-10RαMdelRag1−/− mice, we
measured in whole colons the levels of cytokines implicated in its pathogenesis,
including IL-1β, IL-6, TNF-α, MCP-1, IL-10, IL-17, and
IFN-γ[31]. With
early disease (wk 4), IL-1β, IL-6, and MCP-1 were increased in
IL-10RαMdelRag1−/− colon
compared with Rag1−/− controls (Fig. 4a). As disease progressed (wk 8), the quantity
of cytokine produced was altered. Additional elevations in IL-17 and
TNF-α were identified at this time. Differences in IL-10 and
IFN-γ were not seen.
Figure 4
Cytokine production by colonic macrophages
(A) Colons from Rag1−/− and
IL-10RαMdelRag1−/− mice, 8 wk
after colitis induction, were homogenized and cytokines (IL-1β, IL-6,
TNF-α, MCP-1, IL-10, IL-17 and IFN-γ) measured by ELISA or
multiplex assay. Results from individual mice (circles) and cohort means (lines)
are plotted. (B and C) Percent and absolute number of IL-17+
and IFN-γ+ cells among CD4+ T
cells from colons of diseased mice (8 wk). (D) Relative expression of the
indicated mRNAs (IL-1β, IL-6, IL-23p19 and iNOS) from LPMϕs,
DCs, neutrophils and epithelial cells sorted from colon tissue and measured by
qRT-PCR. (E) Relative expression of the indicated mRNAs (TNF-α, IL-17,
IL-12p40, IL-10, and arginase) from LPMϕs sorted from colon tissue and
measured by qRT-PCR. Data are representative of three independent experiments,
n=10 per cohort. *, p<0.05; **, p<0.01,
***, p<0.001 (by t-test).
T cell transfer colitis is associated with colonic infiltration by both
Th1 and Th17 cells, and the Th17 response is required for disease development.
Our identification of increased colonic IL-6 and IL-1β in
IL-10RαMdelRag1−/− mice,
cytokines associated with Th17 induction, coupled with elevated IL-17 but not
IFN-γ levels implied an intensification of the Th17 response. To test
this, we enumerated IFN-γ and IL-17 producing T cells in the colonic
infiltrate. Significantly increased percents and absolute numbers of
CD4+IL-17A+ T cells were identified in
IL-10RαMdel Rag1−/− compared
with Rag1−/− colons (Fig. 4b). Likewise, after the induction of disease with
CD4+CD25−CD45RBhi
RORγT-GFP reporter T cells, increased GFP+ T cells
were identified in the colon at 4 and 8 wk (Supplementary Fig. 4a). No
differences in CD4+IFN-γ+ T cell
quantities were evident (Fig. 4c).To more specifically determine whether elevated production of
Th17-promoting cytokines was specific to the Mϕ population, we sorted
colonic
CD11bhiCD11c−/lo/modF4/80+Ly6G−/loSiglecF−
LPMϕs from colitic mice and assayed their cytokine expression profiles
by qRT-PCR. A particularly prominent elevation in IL-1β production was
apparent in IL-10RαMdelRag1−/−
compared with Rag1−/− LPMϕs (mRNA expression
ratio: 7.5±1.2). Lesser elevations in IL-6 (3.4±0.5), IL-23
(2.9±0.3) and other pro-inflammatory cytokines were also identified
(Fig. 4d, e). IL-10 itself was
unchanged and a modest decline in arginase with a corresponding increase in iNOS
further indicated enhanced pro-inflammatory function of the
IL-10RαMdelRag1−/−
LPMϕs. For IL-1β, IL-6, IL-23p19, and iNOS, relative expression
was compared in sorted colonic LPMϕs, DCs, neutrophils, and epithelial
cells (Fig. 4d). Elevated expression was
specific to the Mϕs, indicating that Mϕs are the primary source
for the increased Th17-associated cytokines and implying that IL-10 acts
directly on these cells to suppress their production.As an alternative gating strategy, we also sorted
CD11b+CD64+CD103−CD45+Ly6Chi
LPMϕs and assessed similarly for IL-1β, IL-6, IL-23, IL-10,
iNOS, and arginase. These were differentially expressed in a manner paralleling
results above (Supplementary
Fig. 4b). CD163 was additionally assessed as a marker for
anti-inflammatory macrophages and found to be similar in the
IL-10RαMdelRag1−/− and control
Rag1−/− populations.
Colitis in IL-10RαMdelRag1−/−
mice is Th17 dependent
Th17 cells have been shown to be essential to T cell transfer colitis in
Rag1−/− mice[32]. The elevated colonic inflammation in
IL-10RαMdelRag1−/− mice was
correlated with an increased Th17 response, but may also have been mediated by
alternative pathologic pathways. To verify a role for Th17 cells, we transferred
RORγT−/− T cells into
Rag1−/− and
IL-10RαMdelRag1−/− recipients
(Supplementary Fig.
5). RORγT, and hence Th17 cells, proved essential for colitis
in both recipient types.
Colitis is IL-6 independent in
IL-10RαMdelRag1−/−
mice
Though IL-6 is well established as a key inducer of Th17 cells, its
isolated role in fostering the Th17 response fundamental to T cell transfer
colitis has not been addressed. The increased IL-6 in
IL-10RαMdelRag1−/− mice might
have driven the increased immunopathology there. To assess this, we induced
colitis by transfers of IL-6Rα−/− or WT naive
T cells into IL-10RαMdelRag1−/−
and Rag1−/− recipients.
IL-6Rα−/− T cells were ineffective in
inducing disease in Rag1−/− mice (Fig. 5a, b). Mice gained weight after T cell transfer
and histologic lesions were mild. In contrast,
IL-6Rα−/− and WT T cells proved
equipotent in mediating severe clinical disease in
IL-10RαMdelRag1−/− recipients.
Although there was a trend toward modestly diminished histologic severity after
IL-6Rα−/− transfer, this was not
significant. Thus, the Mϕ response to IL-10 creates a dependency for
IL-6 in disease pathogenesis.
Figure 5
Role of T cell IL-6 response in colitis development in
Rag1−/− and
IL-10RαMdelRag1−/−
mice
Colitis was induced in Rag1−/− and
IL-10RαMdelRag1−/− mice by the
transfer of 5×105 C57BL/6 or
IL-6Rα−/−
CD4+CD25−CD45RBhi T cells.
Mice were sacrificed after 8 wk. (A) Representative weight curves, mean
±1 s.e.m., are plotted. *,
WT→Rag1−/− vs
IL-6Rα−/−
→Rag1−/−; △,
WT→Rag1−/− vs
WT→IL-10RαMdelRag1−/−;
□, IL-6Rα−/−
→Rag1−/− vs
IL-6Rα−/−
→IL-10RαMdelRag1−/−;
p<0.05, p<0.01, and p<0.001 for 1, 2, and 3 symbols (by ANOVA). No
significant differences were observed for
WT→IL-10RαMdelRag1−/−
vs IL-6Rα−/−
→IL-10RαMdelRag1−/−.
(B) Histologic scores for colons analyzed at 8 wk. (C) Percent and absolute
number of IL-17+ cells among CD4+ T cells
in the spleen, MLN and colon. (D) Absolute numbers of CD4+ T
cells. (E) Percent and absolute number of IFN-γ+
cells among CD4+ T cells. (F) Percent and absolute number of
Foxp3+ Treg cells among CD4+ T cells.
*, p<0.05; **, p<0.01;
***, p<0.001 (by t-test). Data are representative of
three independent experiments, n=8 per cohort.
To better understand this, we analyzed the T cell responses leading to
colonic injury. Th17 cell percentages among
CD4+TCR+ T cells were reduced in the
MLNs of mice receiving IL-6Rα−/− T cells
(Fig. 5c). This was true for both
IL-10RαMdelRag1−/− and
Rag1−/− mice. Thus IL-6Rα signaling
supports but is not essential for Th17 formation in the MLNs of both of these
recipient lines. In the colon, the representation of Th17 cells was
significantly decreased in Rag1−/− but not
IL-10RαMdelRag1−/− recipients.
This indicates a relative expansion of Th17 cells at the site of autoimmune
inflammation specifically in
IL-10RαMdelRag1−/− mice.Absolute numbers of Th17 cells in all organs sampled dramatically
differed between Rag1−/− and
IL-10RαMdelRag1−/− recipients
of IL-6Rα−/− T cells. Few Th17 cells were
present in the spleens, MLNs, and colons of Rag1−/−
recipients, whereas large numbers were present in
IL-10RαMdelRag1−/− recipients
(Fig. 5c). This difference reflected a
pervasive decrease in total T cell number with the
IL-6Rα−/−→Rag1−/−
transfers (Fig. 5d). Therefore, IL-6 is
broadly necessary for T cell expansion and colitis in
Rag1−/− but dispensable in
IL-10RαMdelRag1−/− mice.
IL-10’s actions on Mϕs generate an IL-6 requirement for
autoinflammatory disease and robust T cell expansion.In contrast to Th17 development, no differences were identified in the
proportions of Th1 or Foxp3+ CD4+ T cells
in any of the transfer combinations tested, indicating that T cell IL-6 and
Mϕ IL-10 responses do not similarly skew these maturation pathways
(Fig. 5e, f). However, absolute numbers
of Th1 and Foxp3+ cells were diminished in the
IL-6Rα−/−
→Rag1−/− combination, again reflecting
the impaired T cell expansion in the absence of disease development.
IL-1 response is required for
IL-10RαMdelRag1−/−
colitis
IL-1β plays an essential role in the steady-state development of
intestinal Th17 cells in healthy mice[33] and further promotes the Th17 response during
colitis[34]. Considering
this, the lack of a requirement for IL-6 in
IL-10RαMdelRag1−/− mice (Fig. 5a, b), and the dramatically elevated
IL-1β expression in
IL-10RαMdelRag1−/−
LPMϕs (Fig. 4), we hypothesized
that IL-1β plays a pathologic role in
IL-10RαMdelRag1−/− mice that
is able to supersede the IL-6 requirement for colitis. To test IL-1’s
impact, we induced colitis by transferring IL-1R−/− T
cells into IL-10RαMdelRag1−/− and
Rag1−/− recipients.IL-1R−/− T cell transfers into
Rag1−/− mice did not lead to the virtually
complete disease protection seen after
IL-6Rα−/− T cell transfers. However
IL-1R−/−
→Rag1−/− transfers did show diminished
clinical and histologic measures of colitis compared with control WT T cell
transfers (Fig. 6a, b).
IL-1R−/− T cells also provoked significantly
milder disease than WT T cells In
IL-10RαMdelRag1−/− recipients
(Fig. 6a, b). This contrasts with
IL-6Rα−/− T cells, which did not
detectably alter disease severity. Therefore, while T cell IL-6 responsiveness
is clinically important only in Rag1−/− colitis, T
cell IL-1 response modulates both Rag1−/− and
IL-10RαMdelRag1−/−
disease.
Figure 6
Role of T cell IL-1 response in colitis development in
Rag1−/− and
IL-10RαMdelRag1−/−
mice
Colitis was induced in Rag1−/− and
IL-10RαMdelRag1−/− mice by the
transfer of 5×105 C57BL/6 or
IL-1R−/−
CD4+CD25−CD45RBhi T cells.
Mice were sacrificed after 8 wk. (A) Representative weight curves, mean
±1 s.e.m., are plotted. *,
WT→Rag1−/− vs
IL-1R−/−
→Rag1−/−; ○,
WT→IL-10RαMdelRag1−/−
vs IL-1R−/− →
IL-10RαMdelRag1−/− △,
WT→Rag1−/− vs
WT→IL-10RαMdelRag1−/−;
□, IL-1R−/−
→Rag1−/− vs
IL-1R−/−
→IL-10RαMdelRag1−/−;
p<0.01, and p<0.001 for 2 and 3 symbols (by ANOVA). (B) Histologic scores
for colons analyzed at 8 wk. (C) Percent and absolute number of
IL-17+ cells among CD4+ T cells in the
spleen, MLN and colon. (D) Percent and absolute number of
IFN-γ+ cells among CD4+ T
cells. (E) Percent and absolute number of Foxp3+ Treg cells
among CD4+ T cells. *, p<0.05; **,
p<0.01; ***, p<0.001 (by t-test). Data are
representative of three independent experiments, n=8 per cohort.
We performed similar analyses of the impact on T cell responses after
IL-1R−/− transfers as for the
IL-6Rα−/− transfers above. Whereas a
decreased percent and absolute number of Th17 cells was seen in the MLNs, a site
of T cell priming, after IL-6Rα−/− transfers
(Fig. 5c), no differences in the MLNs
were seen for IL-10RαMdelRag1−/−
or Rag1−/− recipients receiving
IL-1R−/− compared with WT T cells (Fig. 6c). However, substantially diminished
proportions and absolute numbers of Th17 cells were seen in the colons of mice
receiving IL-1R−/− T cells. The actions of IL-1 were
specific to Th17 effectors; no differences were identified in Th1 and
Foxp3+ Treg populations (Fig. 6d, e). This indicates that there is a selective defect in the
Th17 response in the colon. T cell IL-1 but not IL-6 response in
IL-10RαMdelRag1−/− mice
promotes colonic inflammation by supporting Th17 cells at the site of
autoinflammatory disease. In Rag1−/− mice, where
IL-10 suppresses LPMϕ IL-1β production, IL-6 plays a more
critical role.
Il-10 inhibits pro-IL-1β production and maturation
Our data indicated that IL-1β, increased in the colon of
IL-10RαMdel mice, supports the pathologic Th17 response
mediating colitis. IL-10 inhibits this IL-1β production thereby
attenuating disease. To determine whether IL-1β protein in the colon is
primarily produced by LPMϕs, we used immunohistochemistry to colocalize
IL-1β and CD11b in colon sections from diseased
IL-10RαMdelRag1−/− and
Rag1−/− mice (Supplementary Fig. 6a). This
demonstrated that IL-1β is largely associated with the
CD11b+ population.IL-1β is generated from an inactive cytosolic precursor
(pro-IL-1β). Caspase-1 cleaves pro-IL-1β, converting it into its
active form which is then released from the cell[35]. Caspase-1, in turn, is activated by
inflammasome stimulation[36]. To
better evaluate the impact of IL-10 signaling on IL-1β production by
LPMϕs, we first quantified pro-IL-1β levels by flow cytometry in
gated
CD11bhiCD11c−/lo/modF4/80+Ly6G−/loSiglecF−
Mϕs. This demonstrated a 1.7-fold elevation in the percent of
LPMϕs expressing pro-IL-1β in the colons of diseased
IL-10RαMdelRag1−/− compared
with Rag1−/− mice (mean±s.d.:
84.6±6.0% vs 48.6±8.4%; Fig. 7a). Further, the MFI of positive cells from
IL-10RαMdelRag1−/− mice was
nearly 2-fold greater than that from control mice (131.4±9.3 vs
76.6±5.7). In contrast to the colons of diseased mice, pro-IL-1β
levels were low to undetectable in MLN and bone marrow macrophages, and levels
did not differ between
IL-10RαMdelRag1−/− mice and
Rag1−/− controls. Differences in
pro-IL-1β were also not apparent in mice in which disease was not
induced (Supplementary Fig.
6b).
Figure 7
IL-10 inhibition of Mϕ inflammasome activity and IL-1β
production
(A) Colitis was induced in Rag1−/− and
IL-10RαMdelRag1−/− mice by
transfer of 5×105
CD4+CD25−CD45RBhi T cells
from WT mice. After 8 wks, LPMϕ pro-IL-1β expression was
assessed by intracellular staining. Percent of Mϕs expressing
pro-IL-1β and mean fluorescence intensity (MFI) of positive cells are
plotted. Data are representative of three independent experiments, n=5
per cohort. ***, p<0.001 (by t-test). (B)
Rag1−/− and
IL-10RαMdelRag1−/− BMDMs were
pretreated with recombinant murine IL-10 or blocking anti-IL-10Rα Ab for
4 h prior to the addition of LPS for 12 h and ATP for the final 30 minutes.
Lysates were immunoblotted for IL-1β, caspase-1, and GAPDH. (C)
Naïve CD4+ T cells from WT or
IL-1R−/− mice and LPMϕs from colitic
Rag1−/− and
IL-10RαMdelRag1−/− mice were
purified by flow cytometric sorting. The T cells were stimulated with anti-CD3
and anti-CD28 in the presence of anti-IL-4, anti-IFN-γ, and
TGF-β. LPMϕs and T cell source, and the addition of blocking
anti-IL-6R Ab are indicated. After 4 d, IL-17-producing cells were analyzed by
intracellular staining.
We verified that pro-IL-1β was directly regulated in Mϕ
by IL-10, analyzing its production in cultured and LPS and ATP-stimulated
Mϕ by Western analysis, and simultaneously assessing for mature
IL-1β formation (Fig. 7b and Supplemenatary Fig. 7).
Substantially lower amounts of both pro-IL-1β and IL-1β were
present in cultures of Rag1−/− than
IL-10RαMdelRag1−/− Mϕ.
After treatment with IL-10, pro-IL-β was diminished and mature
IL-1β undetectable in Rag1−/− cultures, while
this manipulation had no effect on
IL-10RαMdelRag1−/−-derived
Mϕs. In contrast, treatment with blocking anti-IL-10R antibody elevated
Rag1−/− pro-IL-1β and IL-1β
levels to those seen with
IL-10RαMdelRag1−/−
Mϕs.The complete suppression of IL-1β maturation by IL-10 suggested
that Mϕ IL-10R signaling also suppressed caspase-1-activation. To test
this we assessed for caspase-1 cleavage to its activated form. LPS and ATP
stimulation of Rag1−/− Mϕs led to a modest
increase in activated caspase-1 (p20, Fig.
7b and Supplementary Fig. 7). Pre-treatment of
Rag1−/− Mϕs with IL-10, however,
abrogated this induction. In contrast, pre-treatment with anti-IL-10Rα
Ab markedly increased activated caspase-1, indicating that autocrine IL-10
normally restrains caspase-1 activation. In the
IL-10RαMdelRag1−/−
Mϕs, p20 formation was similarly increased regardless of IL-10 or
anti-IL-10Rα Ab treatment.To determine whether increased IL-1 and IL-6 from LPMϕs can also
directly impact Th17 cell maturation, we sorted LPMϕs from diseased
IL-10RαMdelRag1−/− and control
Rag1−/− mice, and co-cultured them with
naïve T cells in the presence of added TGFβ but not IL-6. Some
Th17 formed in the presence of Rag1−/− LPMϕs,
however, this was markedly elevated with
IL-10RαMdelRag1−/−
LPMϕs (Fig. 7c). Addition of
αIL-6Rα blocking antibody largely abrogated Th17 formation with
Rag1−/− LPMϕs. However, consistent with
our in vivo findings after IL-6R−/−
T cell transfer, this effect was modest with
IL-10RαMdelRag1−/−-derived
LPMϕs. Blocking IL-1 signaling led to more substantial inhibition of
Th17 development in IL-10RαMdel
Rag1−/−-derived LPMϕs and inhibition of
signaling by both cytokines essentially abrogated Th17 formation. Therefore,
IL-10 can act on LPMϕs to directly impair their support of Th17
production. This occurs through the downregulation of IL-1 and to a lesser
extent IL-6.
Discussion
IL-10’s anti-inflammatory signals maintain intestinal homeostasis.
Yet the essential targets and mechanisms of IL-10 action are incompletely
understood. Recent data has provided support for a myeloid response to IL-10 in
restraining colonic inflammation, and indicated a critical role for IL-10 in the
production of anti-inflammatory LPMϕs that are essential for maintaining
immune homeostasis[19, 20]. We demonstrate here that Mϕs are
the primary targets of IL-10 limiting colitis after naive T cell transfer into
immunodeficientmice. We further identify how the macrophage-specific response to
IL-10 skews the production and expansion of pathologic T cells, thereby promoting
disease exacerbation. Colitis is Th17 dependent regardless of Mϕ IL-10
response. However, we show that IL-10 converts the disease from one that is
independent of the Th17 inducing cytokine IL-6 to one that is highly dependent. In
Rag1−/− recipients of
CD4+CD45RBhi T cells, T cell responsiveness to
IL-6 is necessary for Th17 formation and colitis development. However, in
IL-10RαMdelRag1−/− recipients of
IL-6Rα−/− T cells, a strong Th17
amplification occurs. Colitis develops that is clinically indistinguishable from
that in recipients of IL-6RαWT T cells.Our results further indicate that the Mϕ response to IL-10
downmodulates multiple pro-inflammatory cytokines in the colon, but its impact on
IL-1β, recently documented to regulate Th17 formation during
colitis[34], appears
paramount. IL-10 therefore shifts the cytokine requirements for the Th17 response.
In IL-10’s absence, redundancy between IL-1β and IL-6 supports
persistent colitis. Implicitly, though monotherapy with anti-IL-6 may be promising,
tandem inhibition of the IL-1 pathway may be necessary for optimal suppression of
the Th17 response in IBD, particularly where IL-10 signaling is attenuated.Previous studies have indicated a role for IL-1β in promoting Th17
development both in humans and mice[34,
37, 38]. IL-1β levels in
IL-10−/− mice with colitis are elevated[39] and we extend this finding here to
show that a Mϕ-selective deficit in IL-10 response is sufficient for this.
Prior in vitro findings have also indicated that IL-1β
synergizes with IL-23 to promote Th17 expansion[7], and we did observe increased IL-23 along with IL-1β
production by IL-10Rα-deficient macrophages.Though we and others have identified an essential role for
RORγT+ Th17 cells in colitis and elevated Th17 cells
and/or cytokines have been observed in patients with IBD, the actual role of IL-17
itself is controversial and in a randomized control trial anti-IL-17A proved
ineffective in Crohn’s disease[40]. Identifying effector mechanisms responsible for Th17 mediated
immunopathology during colitis will be important as new therapeutic strategies are
developed.Zigmond, et. al., recently found that mice with a CX3CR1-restricted
IL-10Rα deficiency develop spontaneous colitis[19]. This was hypothesized to be mediated by
defective macrophage regulation by IL-10. Our findings are consistent with this and
with a unique defining role for macrophages in colitis susceptibility. CX3CR1 is
also expressed by DCs[41] and
monocytes[42], and by using
IL-10RαDCdelRag1−/−,
IL-10RαMdelRag1−/−,
IL-10Rα−/−Rag1−/−
and neutrophil specific depleted mice, our findings support a dominant role for
IL-10 action on macrophages in colitis development. This identification of
Mϕ as a key target of IL-10 is consistent with a recently published report
showing that ATP derived from commensal bacteria promotes Th17 differentiation
through a subset of CD11c−/low LP cells[43]. Unlike Zigmond, et. al., we did not observe
spontaneous autoimmunity in our animals, Differences in microflora, and particularly
the presence of Helicobacter spp., may account for this. Our colony
is maintained under helicobacter-free conditions, whereas Zigmond, et. al. report
the presence of helicobacter. Consistently, helicobacter-free IL-10 deficient mice
are protected from spontaneous disease[44]. Alternatively, differences in the subsets of Mϕs
expressing the CX3CR1 versus Lys-M promoters, may distinguish spontaneous disease
susceptibility in our two systems, and this needs to be further explored.Shouval, et. al. recently identified a prominent role for IL-10Rβ
signaling into myeloid cells in suppressing colitis development. A significant
diminution of the Foxp3+ regulatory T cell response was seen. We
did not identify a discernible effect of Mϕ IL-10Rα deficiency on
iTreg development or transferred nTreg function. This will need resolution.
IL-10Rβ is also utilized by IL-22, IL-26 and IFN-λ, which might
explain the differences. Alternatively, cell types besides Lys-M+
macrophages may provide critical signals supporting Treg formation and maintenance,
and IL-10 may be necessary for this. Regardless of these differences, Shouval, et.
al. demonstrated a strongly pro-inflammatory phenotype of
IL-10Rβ−/− BMDM, and extended this to
Mϕs from IL-10R deficient patients, implying that these regulatory mechanics
are translatable to human IBD. Cumulatively, these data provide strong evidence for
macrophage as the critical target of IL-10, and assert several mechanisms through
which this occurs.After transfers of IL-6Rα-deficient T cells, we identified a
decreased percent of Th17 cells in the MLN but not colon of
IL-10RαMdelRag1−/− recipients.
This may imply that Th17 cells primed in the MLN are amplified by IL-1β in
the colon. However, the site(s) of priming of the Th17 response in colitis is not
defined and it is possible that additional priming occurs within gut-associated
lymphoid tissue itself. In this regards, we show that isolated LPMϕs from
IL-10RαMdelRag1−/− mice have an
enhanced ability to support Th17 development from naïve T cells. Hence,
although without being able to track the initial site of pathologic T cell
development we cannot distinguish whether IL-1β in our system is acting at
priming or expansion of Th17 cells, increased colonic Mϕ IL-1β
production can support either or both of these mechanisms.Our results here are consistent with data demonstrating that IL-10 acts via
STAT3 to suppress pro-IL-1β production[45]. Moreover, we extend these findings, showing that IL-10
further inhibits caspase-1 activity. Caspase-1 is activated through inflammasome
induced oligomerization and autocatalytic cleavage and it will be important to
identify the precise site at which IL-10 acts within the inflammasome cascade.Though our study specifically interrogates the IL-10 response during
colitis, its implications may extend beyond this. IL-1β also promotes the
Th17 response in Helicobacter hepaticuscolitis[34]. Administration of rIL-1-β
selectively induced Th17 cells in the steady-state intestinal environment[33]. High levels of IL-1β are
associated with an amplified Th17 response in autoimmune RA and EAE models[46-48]. These effects of IL-1β on Th17 cells may be
similarly IL-10 and Mϕ dependent, and this can be assessed using the
conditional knock-out mice we have developed.Our results, as those using a Tg DN IL-10R[24], do not support transferred naïve T
cells as a significant target of IL-10 in this model. This does not indicate that
IL-10 is not a significant T cell regulator. The effects of IL-10 on T cells is
complex, and system and T cell subset dependent. Thus, the Treg response to IL-10
was found to sustain Treg in colitis, and mice with a Treg-selective deletion of
IL-10R developed spontaneous colitis[18,
21]. Likewise, we have
identified direct effects of IL-10 on T cells in regulating myelin-specific
responses during experimental autoimmune encephalomyelitis[25].It will also be important to identify the source of IL-10 relevant to
Mϕ targets. Our findings here and those of others indicate that neither
effector nor the adaptive regulatory T cells that form after naïve T cell
transfer are relevant sources[49].
In contrast, purified and adoptively transferred IL-10−/−
Tregs were seen to be less potent than WT Tregs in preventing and treating
established colitis, indicating that TregIL-10 is significant in some
circumstances. However, Treg only account for a portion of IL-10’s
effects[49-51]. The absence of a physiologically
relevant T cell IL-10 source here may suggest a myeloid source. Mϕ
themselves are strong IL-10 producers and autocrine IL-10 signaling may well provide
necessary signals that prevent overzealous Mϕ reactions. Indeed, we
identified substantial IL-10 mediated autoregulation of pro-IL-1β production
and caspase-1 activation in cultured Mϕ (Fig.
7). In contrast, Zigmond et. al. found no role for
CX3CR1+ macrophage-produced IL-10 in the spontaneous colitis
that they observed[19], potentially
implying that multiple sources may be relevant.In summary, we show that the Mϕ response to IL-10 is critical for
Th17 development during colitis. Further, IL-10’s suppression of
pro-inflammatory cytokine production does not obviate the essential role for Th17
cells but does shift the cytokine requirements for that response from one primarily
governed through IL-1β to one that is IL-6 dependent.
Methods
Mice
We previously produced and verified correct targeting of
IL-10Rαfl/fl mice and lineage specific IL-10Rα
deletions on a C57BL/6 background as described in prior publications[25, 26]. These were bred with B6.129S7-Rag1tm1Mom/J
mice. B6.129P2-IL-10tm1Cgn/J, B6.129P2-Rorctm1Litt/J,
B6.129S7-Il1r1tm1mx/J,
B6.129(Cg)-Foxp3/J, and
B6;SJL-Il6Rαtm1.1Drew/J mice were obtained from The
Jackson Laboratories. Colonies were maintained under spf, including detectable
Helicobacter spp.-free, conditions. Mice of either sex were
between 8 and 12 weeks of age at the time of study, and paired between
experimental and control groups. Experimental protocols were approved by the St.
Jude Animal Care and Use Committee.
Induction of colitis
Flow cytometrically sorted
CD4+CD25−CD45RBhi T cells
(5×105/mouse) derived from pooled splenocytes and LN
cells of indicated mice were transferred i.v. into
Rag1−/− or
IL-10RαMdelRag1−/− mice. Body
weight was monitored on a weekly basis. For neutrophil depletion studies, 1 mg
anti-Ly6G mAb 1A8 (Bio-X-Cell) or control IgG[26] was administered per mouse i.p. 1 d
before cell transfer and weekly thereafter. Depletion was confirmed by flow
cytometry. For analyses of Treg-mediated disease suppression, splenocytes from
Foxp3-YFP reporter mice were collected and naïve T cells, defined as
CD4+CD45RBhiYFP−, and Treg
cells, defined as
CD4+CD45RBlowYFP+, sorted.
Purity after sorting was >99%. Age-matched
Rag1−/− mice or
IL-10RαMdelRag1−/− mice
received 2×105 naive T cells with or without Treg cells at a
1:1 ratio i.v.
Histology
Colons were stained with hematoxylin and eosin. Three independent
sections were assessed per mouse by a blinded reviewer. Inflammation scoring: 0,
no or occasional inflammatory cells in the lamina propria (LP); 1, increased LP
inflammatory cells; 2, confluence of inflammatory cells extending into the
submucosa; 3, transmural infiltrate extension of the infiltrate. Ulceration
scoring: 0, no ulceration; 1, mild (1–2 ulcers per 40 crypts analyzed);
2, moderate (3–4 ulcers); 3, severe (> 4 ulcers). Hyperplasia
scoring: 0, normal; 1, crypts up to twice normal thickness with normal
epithelium; 2, crypts >2 times normal thickness, hyperchromatic epithelium;
reduced goblet cells, scattered arborization; 3, Crypts >4 times normal
thickness, marked hyperchromasia, few to no goblet cells, high mitotic index,
frequent arborization. Disease area scoring: 0, 0–5%
involvement; 1, 5–30%; 2, 30–70%; 3,
>70%. Total score is the sum of individual scores.
Cytokine levels
Frozen colon samples were homogenized in ice-cold PBS containing
1% NP-40 and complete protease inhibitor cocktail (Roche). Cytokines and
chemokines were measured by Luminex (Bio-Rad) or ELISA (R&D Systems).
LP cell isolation
LP cells were isolated using a modification of a previously described
protocol[26]. Large
intestines were carefully excised, mesentery and fat removed, and intestines
then opened longitudinally, rinsed in HBSS and cut into 1-cm pieces. Colon
segments were vigorously shaken twice in medium with 1 mM EDTA (Sigma-Aldrich)
for 20 min at 37°C, and suspended cells collected and filtered through a
cell strainer. Tissue was further minced and incubated at 37°C for 1 h
in medium with 1 mM collagenase type IV (Sigma-Aldrich) and 40 U
ml−1 DNase I (Roche) with agitation. Cells were filtered,
washed, and isolated over a percoll step gradient.
Cytokine PCR
Total RNA was isolated from sorted LPMϕs using the RNeasy mini
kit (Qiagen), and cDNA synthesized using superscript III and oligo (dT) primers
(Invitrogen). Expression levels of were normalized to HPRT (ΔCt) and
compared with littermate controls using the ΔΔCt
method[52]. Primer
sequences are: TGF-β: F, CAC AGT ACA GCA AGG TCC TTG C; R, AGT AGA CGA
TGG GCA GTG GCT; IL-12p35: F, ATG ACC CTG TGC CTT GGT AG; R, GAT TCT GAA GTG CTG
CGT TG; IL-23p19: F, AGC GGG ACA TAT GAA TCT ACT AAG AGA; R, GTC CTA GTA GGG AGG
TGTGAA GTT; IL-12p40: F, GAC CAT CAC TGT CAA AGA GTT TCT AGA T; R, AGG AAA GTC
TTG TTT TTG AAA TTT TTT AA; IL-1β: F, GAT CCA CAC TCT CCA GCT GCA; R,
CAA CCA ACA AGTGAT ATT CTC CATG; IL-10: F, GTG AAA ATA AGA GCA AGG CAG TG; R,
ATT CAT GGC CTT GTA GAC ACC; TNF-α: F, AAT GGC CTC CCT CTC ATC AGT; R,
CTA CAG GCT TGT CAC TCG AA; iNOS: F, TGA CGG CAA ACA TGA CTT CAG; R, GCC ATC GGG
CAT CTG GTA; IL-6: F, TAT GAA GTT CCT CTC TGC AAG AGA; R, TAG GGA AGG CCG TGG
TT; Arginase: F, TCA CTT TCC ACC ACC TCT TG AY; R, TCT CCA CCG CCT CAC GAC TC;
IL-17A: F, GCT CCA GAA GGC CCT CAG, R, CTT TCC CTC CGC ATT GAC A; CD163: F, CCT
TGG AAA CAG AGA CAG GC; R, TCC ACA CGT CCA GAA CAG TC; HPRT: F, GA CCG GTC CCG
TCA TGC; R, TCA TAA CCT GGT TCAT CAT CGC. F, forward primer; R, reverse
primer.
Flow cytometry
Cells were stained with Abs specific for mouse TCRβ, F4/80,
CD11b, CD11c, CD40, CD64, CD80, CD86, Ly6G, Siglec-F, CD4, Foxp3, IL-17,
IFN-γ, pro-IL-1β, or with isotype-matched controls (1:100
dilution for each antibody; BD Pharmingen or eBiosciences), and analyzed using a
FACSCalibur or LSRII flow cytometer with Cell Quest (BD Biosciences) or FlowJo
(TreeStar) software.
BRDU staining
Mice were injected i.p. with 150 μl BrdU (10 mg
ml−1) in sterile 1× DPBS. After 16–20 h,
lymphocytes were isolated, stained with Abs to cell surface markers, fixed and
permeabilized with Cytofix/Cytoperm Buffer (BD Biosciences), treated with DNase
(300 μg ml−1) at 37°C for 1 h, stained with
anti–BrdU-APC (BD BRDU flow kit), and analyzed by flow cytometry.
BMDM culture and LPS stimulation
BMDMs were generated by culturing mouse bone marrow cells in
L-cell-conditioned IMDM. The L-cell conditioned medium comprised supernant from
cultures of L929 cells secreting M-CSF mixed at a 1:2 ratio with IMDM and then
supplemented with 10% FBS, 1% non-essential amino acids and
1% penicillin–streptomycin. After 6 days of culture, cells were
seeded in 12-well plates, and the next day treated with IL-10 (50ng
ml−1) or anti-IL-10Rα Ab (1μg
ml−1), and 4 h later stimulated with or without LPS (20
ng ml−1) for 12 h. For the final 30 min, 5mM ATP was added
into the medium[53].
Western blot
Culture samples were denatured in loading buffer containing SDS and 100
mM DTT, and boiled for 5 min. SDS-PAGE–separated proteins were
transferred to polyvinylidene difluoride membranes and immunoblotted with
primary Abs against caspase-1 (Adipogen; AG-20B-0042 or kind gift of Dr Peter
Vandenabeele, Ghent University), IL-1β (R&D Systems), and GAPDH
(Cell Signaling Technology; D16H11), followed by secondary anti-rabbit,
anti-rat, anti-mouse, or anti-goat HRP Abs (Jackson ImmunoResearch
Laboratories)[54].
Images have been cropped for presentation. Full size images are presented in
Supplementary Fig.
7.
Th17 culture
Naive
(CD4+CD45RBhighCD25−) T
cells were purified by cell sorting to a purity >99%. These
(5×105) were co-cultured at a ratio of 5:1 with or
without sorted LPMϕs from 8 week diseased IL-10RαMdel
Rag1−/− or Rag1−/−
mice in 96-well plates pre-coated with 1 μg ml−1
anti-CD3 and 2 μg ml−1 anti-CD28. Cells were cultured
in complete RPMI 1640 media containing 5 ng ml−1
TGF-β, 10 μg ml−1 anti-IL-4 and 10 μg
ml−1 anti-IFN-γ Abs. 20 ng
ml−1 IL-6 was added to a positive control Th17 culture
condition only. After 4 days, cells were washed and restimulated with cytokine
stimulation cocktail containing PMA, Ionomycin and Brefeldin A (Cell stimulation
cocktail, eBioscience) for 4 hours at 37°C. Cells were washed and
stained for the indicated cytokines.
Immunohistochemistry
Tissue cryosections were fixed in 4% PFA at 4°C
overnight, embedded in optimal cutting temperature (OCT) compound, and sectioned
in a cryostat (12 μm). For IL-1β immunostaining, sections were
incubated with a polyclonal goat anti-mouseIL-1β primary antibody
(1:200, R&D Systems) and monoclonal rat anti-mouseCD11b antibody (1:500,
AbD Serotec). After washing 3 times with TBST, sections were incubated with
Cy3-labeled donkey-anti-rat IgG antibody (1:200, Jackson Lab) and Alexa
488-labeled donkey anti-goat IgG antibody (1:200,Molecular Probes). Sections
were mounted with mounting medium containing DAPI (Invitrogen), and confocal
microscopy was performed.
Statistics
Statistics were calculated using Prism5 (GraphPad Software). Group
comparisons were by two-sided Student’s t-test or, when multiple cohorts
were present, ANOVA with Bonferroni correction. A p< 0.05 was considered
significant.
Authors: Moritz Leppkes; Christoph Becker; Ivaylo I Ivanov; Sebastian Hirth; Stefan Wirtz; Clemens Neufert; Sandrine Pouly; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Burkhard Becher; Dan R Littman; Markus F Neurath Journal: Gastroenterology Date: 2008-10-09 Impact factor: 22.682
Authors: Yuri P Rubtsov; Jeffrey P Rasmussen; Emil Y Chi; Jason Fontenot; Luca Castelli; Xin Ye; Piper Treuting; Lisa Siewe; Axel Roers; William R Henderson; Werner Muller; Alexander Y Rudensky Journal: Immunity Date: 2008-04 Impact factor: 31.745
Authors: Rachel Mak'Anyengo; Peter Duewell; Cornelia Reichl; Christine Hörth; Hans-Anton Lehr; Sandra Fischer; Thomas Clavel; Gerald Denk; Simon Hohenester; Sebastian Kobold; Stefan Endres; Max Schnurr; Christian Bauer Journal: JCI Insight Date: 2018-03-08
Authors: Dror S Shouval; Amlan Biswas; Yu Hui Kang; Alexandra E Griffith; Liza Konnikova; Ivan D Mascanfroni; Naresh S Redhu; Sandra M Frei; Michael Field; Andria L Doty; Jeffrey D Goldsmith; Atul K Bhan; Anthony Loizides; Batia Weiss; Baruch Yerushalmi; Tadahiro Yanagi; Xiuli Lui; Francisco J Quintana; Aleixo M Muise; Christoph Klein; Bruce H Horwitz; Sarah C Glover; Athos Bousvaros; Scott B Snapper Journal: Gastroenterology Date: 2016-09-28 Impact factor: 22.682
Authors: Mathilde J H Girard-Madoux; Juliane L Ober-Blöbaum; Léa M M Costes; Junda M Kel; Dicky J Lindenbergh-Kortleve; Inge Brouwers-Haspels; Astrid P Heikema; Janneke N Samsom; Björn E Clausen Journal: Oncotarget Date: 2016-05-31